I was mad about that, too. 👎🏼

Yup, we have one of those

Wonder if that means more acceptances or fewer!

Not sure they want it to work..

This work was led by @rjcorbett.bsky.social and Rebecca Kaufman in partnership with @sjdiskin.bsky.social and many others, especially neuro-oncology experts Suzanne MacFarland, Miriam Bornhorst, Angela Waanders, and Kristina Cole.

🔗 This study is built on rigorous, reproducible multimodal analysis. All code is openly available at github.com/diskin-lab-c....
www.medrxiv.org/content/10.1...

🔎 We also found germline P/LP variation significantly associated with histology-specific tumor methylation, mutational signatures, and clinical outcomes, suggesting that routine germline testing should be considered at diagnosis to guide personalized treatment strategies.

💡 We uncovered new associations between germline P/LP variation and aberrant RNA splicing in 26 patient matched tumors involving novel transcripts. Many were accompanied by RNA expression loss, reduced protein abundance, or disrupted functional domains, suggesting a direct impact on tumor biology.

🔬 We found P/LP variants in CPGs in 24.4% (201/830) of patients—a higher prevalence than previous estimates (8-21%). Many of these variants were not clinically reported, including 47 cases carrying tumor syndrome-associated variants.

I also had the same thought